Pathstone Family Office’s Avanos Medical AVNS Stock Holding History

Pathstone Family Office’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-312	Closed	-$12K	–	402
2017 Q1	$12K	Buy	+312	New	+$12.2K	0.01%	267
2016 Q4	–	Sell	-312	Closed	-$11K	–	107
2016 Q3	$11K	Hold	312	–	–	0.01%	122
2016 Q2	$10K	Buy	+312	New	+$9.56K	0.01%	137

Other funds holding AVNS

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Pathstone Family Office's AVNS Position: Q2 2017 in Review

Pathstone Family Office sold out of Avanos Medical (AVNS) in Q2 2017, closing a stake of 312 shares — an estimated $12K sold.

Pathstone Family Office first reported a position in AVNS in Q2 2016 and held it in 3 quarters. The position peaked at $12K in Q1 2017. 328 funds tracked by Wall St. Rank hold AVNS as of Q2 2017.

Pathstone Family Office reported no remaining Avanos Medical position as of Q2 2017 after selling out during the quarter.
Pathstone Family Office sold 312 Avanos Medical shares in Q2 2017, an estimated $12K.
Pathstone Family Office first reported a position in Avanos Medical in Q2 2016 and held it in 3 quarters.
Pathstone Family Office's Avanos Medical position peaked at $12K in Q1 2017.
328 funds tracked by Wall St. Rank held Avanos Medical as of Q2 2017.

Based on Pathstone Family Office's 13F filing for Q2 2017, filed 11 Aug 2017.